Navigation Links
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Date:3/11/2009

taneous bleeding and bone, joint or tissue hemorrhage. Diminished concentrations of fibrinogen, also called Factor I (one), limit the body's ability to form a clot. Certain fibrinogen levels usually indicate normal blood clotting ability. To determine fibrinogen levels and confirm a diagnosis, blood coagulation testing is needed.

RiaSTAP is a purified fibrinogen concentrate that undergoes virus inactivation and removal for safety assurance. There have been more than 1 million units sold worldwide (marketed outside the U.S. under the trade name Haemocomplettan(R) P). CSL Behring is studying RiaSTAP in an ongoing post-marketing commitment study to further demonstrate safety and hemostatic efficacy.

About RiaSTAP

RiaSTAP is a purified fibrinogen concentrate indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. RiaSTAP is not indicated for dysfibrinogenemia. RiaSTAP is contraindicated in individuals who have had severe immediate hypersensitivity reactions, including anaphylaxis to RiaSTAP or its components.

Physicians should monitor patients for early signs of allergic or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP. Physicians should weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from pooled human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and theoretically the Creutzfeldt-Jakob disease agent (CJD) that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by a process demonstrated to inactivate
'/>"/>

SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
3. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
4. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
5. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
6. deCODE Receives California Clinical Laboratory License
7. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
8. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
9. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
10. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
11. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/22/2014)... 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced ... of common stock and warrants at a price of ... prior to deducting underwriting discounts and commissions and offering ... are immediately separable and will be issued separately.  The ... on The NASDAQ Stock Market under the ticker symbol ...
(Date:8/21/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record in ... laboratory services companies. She has more than 20 years ... she held the position of Director, Lab Services Sales ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... announces that a new market research report is ... RNAi Drug Delivery: Technologies and Global Markets ... THIS REPORT CONTAINS An ... technologies market is applied in therapeutics, research and ...
... China, March 23, 2011 /PRNewswire-Asia/ -- China Medicine Corporation ... a leading manufacturer, developer and distributor of Western pharmaceuticals, ... the People,s Republic of China, today announced that it ... Commission 1) a Current Report on Form 8-K to ...
Cached Medicine Technology:Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 2Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 3Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 5Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 6Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 7Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 8Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 9Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 10Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 11Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 12Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 13Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 14China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing 2China Medicine Corporation Files Extension for Fiscal 2010 Form 10-K Filing 3
(Date:8/22/2014)... (PRWEB) August 22, 2014 Home ... of in-home care for seniors, is proud to announce ... Series. The upcoming webinar will feature Dr. Suzanne Steinbaum, ... Lenox Hill Hospital in New York City, National Spokesperson ... author. The webinar will cover the issues surrounding women ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- Counseling may do little ... review finds. Researchers analyzed 66 studies that included ... were at high risk for drinking problems. Participants in ... participants in the rest of the studies attended group ... A counseling technique called motivational interviewing was used ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Inner city children have a higher-than-normal ... Researchers followed 516 inner city children in four U.S. cities ... birth until age 5 and found that at least 10 ... peanuts. Because only the three most common types of ... of inner city youngsters with food allergies may be even ...
(Date:8/22/2014)... few years, several breakthrough treatments have become available ... may benefit from these treatments can be pre-identified ... cancer. For example, patients whose lung cancer is ... significant benefit from the drug crizotinib, which targets ... attempting to replicate this success by matching different ...
(Date:8/22/2014)... severe disabilities and multiple chronic conditions are screened for ... or no chronic conditions, a new study has found. ... with moderate disabilities or women with only one chronic ... with the Li Ka Shing Knowledge Institute of St. ... often have other measures of social vulnerability, such as ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:Women with severe, chronic health issues are screened for breast cancer less often 2
... , TUESDAY, Aug. 16 (HealthDay News) -- For some ... of the disease who find standard treatments either intolerable ... relief. A new injectable treatment called pegloticase (brand ... patients, but researchers say that for the roughly ...
... Pneumonia kills more children around the world than any ... the causes of childhood pneumonia across many countries was ... study called the Pneumonia Etiology Research for Child Health ... 5 African and 2 Asian research sites coordinated by ...
... was a dramatic increase in the number of children,s flu-related hospital ... agency says. Over that time, flu rose from 65th to ... younger go to the hospital, according to a report from the ... found that skin infections rose from 13th to 7th in the ...
... Foundation launched a major new collaboration created with ... with its announcement that it will provide funding ... interventional radiology during 2012󈝹 in the Howard Hughes ... "The SIR Foundation, which seeks to further ...
... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...
... for 15 minutes a day, or 92 minutes per week, ... who are inactive, according to a study published today in ... reduced deaths from any cause by 14 percent," said study ... The University of Texas MD Anderson Cancer Center Department of ...
Cached Medicine News:Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 2Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 3Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 4Health News:Largest global childhood pneumonia etiology study launched 2Health News:Largest global childhood pneumonia etiology study launched 3Health News:Society of Interventional Radiology Foundation funds Howard Hughes Medical Institute Award 2Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 2Health News:Study finds 15 minutes of moderate daily exercise lengthens life 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: